Search

Your search keyword '"Garcia-Manero, G"' showing total 1,658 results
Start Over Author "Garcia-Manero, G"
1,658 results on '"Garcia-Manero, G"'

1. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

Author

Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., Della Porta, M. G., Cazzola, M., DeZern, A. E., Roboz, G. J., Steensma, D. P., Van de Loosdrecht, A. A., Schlenk, R. F., Grau, J., Calvo, X., Blum, S., Pereira, A., Valent, P., Costa, D., Giagounidis, A., Xicoy, B., Döhner, H., Platzbecker, U., Pedro, C., Lübbert, M., Oiartzabal, I., Díez-Campelo, M., Cedena, M. T., Machherndl-Spandl, S., López-Pavía, M., Baldus, C. D., Martinez-de-Sola, M., Stauder, R., Merchan, B., List, A., Ganster, C., Schroeder, T., Voso, M. T., Pfeilstöcker, M., Sill, H., Hildebrandt, B., Esteve, J., Nomdedeu, B., Cobo, F., Haas, R., Sole, F., Germing, U., Greenberg, P. L., Haase, D., and Sanz, G.

Published
2021
Full Text
View/download PDF

2. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

Author

Daver, N, Kantarjian, H, Ravandi, F, Estey, E, Wang, X, Garcia-Manero, G, Jabbour, E, Konopleva, M, O'Brien, S, Verstovsek, S, Kadia, T, Dinardo, C, Pierce, S, Huang, X, Pemmaraju, N, Diaz-Pines-Mateo, M, Cortes, J, and Borthakur, G

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Orphan Drug, Hematology, Pediatric Cancer, Cancer, Clinical Research, Childhood Leukemia, Clinical Trials and Supportive Activities, Pediatric, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Aminoglycosides, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Decitabine, Female, Gemtuzumab, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Myelodysplastic Syndromes, Sialic Acid Binding Ig-like Lectin 3, Clinical Sciences, Immunology, Cardiovascular medicine and haematology, Clinical sciences, Oncology and carcinogenesis
Abstract

Decitabine may open the chromatin structure of leukemia cells making them accessible to the calicheamicin epitope of gemtuzumab ozogamicin (GO). A total of 110 patients (median age 70 years; range 27-89 years) were treated with decitabine and GO in a trial designed on model-based futility to accommodate subject heterogeneity: group 1: relapsed/refractory acute myeloid leukemia (AML) with complete remission duration (CRD)

Published
2016

3. Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome

Author

Tambaro, FP, Garcia-Manero, G, O'Brien, SM, Faderl, SH, Ferrajoli, A, Burger, JA, Pierce, S, Wang, X, Do, K-A, Kantarjian, HM, Keating, MJ, and Wierda, WG

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Lymphoma, Orphan Drug, Cancer, Pediatric Cancer, Prevention, Childhood Leukemia, Pediatric, Clinical Research, Rare Diseases, Aged, Female, Humans, Karyotype, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Male, Myelodysplastic Syndromes, Retrospective Studies, Clinical Sciences, Immunology, Cardiovascular medicine and haematology, Clinical sciences, Oncology and carcinogenesis
Abstract

Acute leukemia (AL) and myelodysplastic syndrome (MDS) are uncommon in chronic lymphocytic leukemia (CLL). We retrospectively identified 95 patients with CLL, also diagnosed with AL (n=38) or MDS (n=57), either concurrently (n=5) or subsequent (n=90) to CLL diagnosis and report their outcomes. Median number of CLL treatments prior to AL and MDS was 2 (0-9) and 1 (0-8), respectively; the most common regimen was purine analog combined with alkylating agent±CD20 monoclonal antibody. Twelve cases had no prior CLL treatment. Among 38 cases with AL, 33 had acute myelogenous leukemia (AML), 3 had acute lymphoid leukemia (ALL; 1 Philadelphia chromosome positive), 1 had biphenotypic and 1 had extramedullary (bladder) AML. Unfavorable AML karyotype was noted in 26, and intermediate risk in 7 patients. There was no association between survival from AL and number of prior CLL regimens or karyotype. Expression of CD7 on blasts was associated with shorter survival. Among MDS cases, all International Prognostic Scoring System (IPSS) were represented; karyotype was unfavorable in 36, intermediate in 6 and favorable in 12 patients; 10 experienced transformation to AML. Shorter survival from MDS correlated with higher risk IPSS, poor-risk karyotype and increased number of prior CLL treatments. Overall, outcomes for patients with CLL subsequently diagnosed with AL or MDS were very poor; AL/MDS occurred without prior CLL treatment. Effective therapies for these patients are desperately needed.

Published
2016

5. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics

Author

Heinrichs, S, Kulkarni, RV, Bueso-Ramos, CE, Levine, RL, Loh, ML, Li, C, Neuberg, D, Kornblau, SM, Issa, J-P, Gilliland, DG, Garcia-Manero, G, Kantarjian, HM, Estey, EH, and Look, AT

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Genetics, Genetic Testing, Human Genome, Clinical Research, Hematology, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Adult, Aged, Aged, 80 and over, Chromosome Deletion, Female, Humans, Karyotyping, Loss of Heterozygosity, Male, Middle Aged, Myelodysplastic Syndromes, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Uniparental Disomy, myelodysplastic syndrome, SNP array, uniparental disomy, Clinical Sciences, Immunology, Cardiovascular medicine and haematology, Clinical sciences, Oncology and carcinogenesis
Abstract

Progress in the management of patients with myelodysplastic syndromes (MDS) has been hampered by the inability to detect cytogenetic abnormalities in 40-60% of cases. We prospectively analyzed matched pairs of bone marrow and buccal cell (normal) DNA samples from 51 MDS patients by single nucleotide polymorphism (SNP) arrays, and identified somatically acquired clonal genomic abnormalities in 21 patients (41%). Among the 33 patients with normal bone marrow cell karyotypes, 5 (15%) had clonal, somatically acquired aberrations by SNP array analysis, including 4 with segmental uniparental disomies (UPD) and 1 with three separate microdeletions. Each abnormality was detected more readily in CD34+ cells than in unselected bone marrow cells. Paired analysis of bone marrow and buccal cell DNA from each patient was necessary to distinguish true clonal genomic abnormalities from inherited copy number variations and regions with apparent loss of heterozygosity. UPDs affecting chromosome 7q were identified in two patients who had a rapidly deteriorating clinical course despite a low-risk International Prognostic Scoring System score. Further studies of larger numbers of patients will be needed to determine whether 7q UPD detected by SNP array analysis will identify higher risk MDS patients at diagnosis, analogous to those with 7q cytogenetic abnormalities.

Published
2009

6. Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS

Author

Garcia-Manero, G., primary, Bachiashvili, K., additional, Amin, H., additional, Traer, E., additional, Pollyea, D., additional, Sallman, D., additional, Al-Kali, A., additional, Cripe, L., additional, Berdeja, J., additional, Griffiths, E., additional, Mohan, S., additional, Vachhani, P., additional, Sano, Y., additional, Oganesian, A., additional, Keer, H., additional, and Yacoub, A., additional

Published
2023
Full Text
View/download PDF

7. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

Author

Garcia-Manero, G., primary, Bachiashvili, K., additional, Griffiths, E., additional, Traer, E., additional, Saini, L., additional, Amin, H., additional, Zeidan, A., additional, Mohan, S., additional, Lübbert, M., additional, Maness, L., additional, Foran, J., additional, Selleslag, D., additional, Xicoy, B., additional, Pollyea, D., additional, Sallman, D., additional, Al-Kali, A., additional, Berdeja, J., additional, Al-Ali, H., additional, Zhu, N., additional, Lopez, P. Font, additional, Sanz, G., additional, Santini, V., additional, Yimer, H., additional, Cripe, L., additional, Priego, V., additional, Odenike, O., additional, Heyrman, B., additional, Valcárcel, D., additional, Vachhani, P., additional, Sano, Y., additional, Mirakhur, B., additional, Oganesian, A., additional, Keer, H., additional, and Yacoub, A., additional

Published
2023
Full Text
View/download PDF

8. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES

Author

Savona, M., primary, Mccloskey, J., additional, Griffiths, E., additional, Yee, K., additional, Zeidan, A., additional, Al-Kali, A., additional, Deeg, H.J., additional, Patel, P., additional, Sabloff, M., additional, Keating, M.-M., additional, Zhu, N., additional, Gabrail, N., additional, Fazal, S., additional, Maly, J., additional, Odenike, O., additional, Kantarjian, H., additional, Dezern, A., additional, O’Connell, C., additional, Roboz, G., additional, Busque, L., additional, Buckstein, R., additional, Amin, H., additional, Randhawa, J., additional, Leber, B., additional, Dao, K.-H., additional, Sano, Y., additional, Mirakhur, B., additional, Keer, H., additional, and Garcia-Manero, G., additional

Published
2023
Full Text
View/download PDF

9. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)

Author

Kuendgen, A., primary, Nomdedeu, M., additional, Tuechler, H., additional, Garcia-Manero, G., additional, Komrokji, R., additional, Sekeres, M., additional, Della Porta, M., additional, Cazzola, M., additional, Dezern, A., additional, Roboz, G., additional, Steensma, D., additional, Van De Loosdrecht, A., additional, Malcovati, L., additional, Schlenk, R., additional, Grau, J., additional, Calvo, X., additional, Blum, S., additional, Pereira, A., additional, Valent, P., additional, Costa, D., additional, Giagounidis, A., additional, Xicoy, B., additional, Döhner, H., additional, Platzbecker, U., additional, Pedro, C., additional, Lübbert, M., additional, Oiartzabal, I., additional, Diez-Campelo, M., additional, Cedena, M.T., additional, Machherndl-Spandl, S., additional, Lopez-Pavia, M., additional, Martinez-De-Sola, M., additional, Stauder, R., additional, Merchan, B., additional, Ganster, C., additional, Schroeder, T., additional, Voso, M.T., additional, Pfeilstöcker, M., additional, Sill, H., additional, Hildebrandt, B., additional, Esteve, J., additional, Cobo, F., additional, Solé, F., additional, Germing, U., additional, Greenberg, P., additional, Haase, D., additional, and Sanz, G., additional

Published
2023
Full Text
View/download PDF

10. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE

Author

Pfeilstöcker, M., primary, Tuechler, H., additional, Ades, L., additional, Cermak, J., additional, Chermat, F., additional, Della Porta, M., additional, Fenaux, P., additional, Garcia-Manero, G., additional, Germing, U., additional, Haase, D., additional, Kündgen, A., additional, Lübbert, M., additional, Magalhaes, S., additional, Malcovati, L., additional, Miyazaki, Y., additional, Sanz, G., additional, Santini, V., additional, Sekeres, M., additional, Walter, M., additional, Valent, P., additional, and Greenberg, P., additional

Published
2023
Full Text
View/download PDF

11. SINGLE CELL DATA

Author

Ganan-Gomez, I., primary, Chien, K., additional, Adema, V., additional, Ma, F., additional, Yang, H., additional, Montalban-Bravo, G., additional, Rodriguez-Sevilla, J., additional, Tan, L., additional, Lorenzi, P., additional, Clise-Dwyer, K., additional, Garcia-Manero, G., additional, and Colla, S., additional

Published
2023
Full Text
View/download PDF

14. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.

Author

Zeidan, A.M., Platzbecker, U., Bewersdorf, J.P., Stahl, M., Adès, L., Borate, U., Bowen, D., Buckstein, R., Brunner, A., Carraway, H.E., Daver, N., Díez-Campelo, M., Witte, T.J. de, DeZern, A.E., Efficace, F., Garcia-Manero, G., Garcia, J.S., Germing, U., Giagounidis, A., Griffiths, E.A., Hasserjian, R.P., Hellström-Lindberg, E., Iastrebner, M., Komrokji, R., Kulasekararaj, A.G., Malcovati, L., Miyazaki, Y., Odenike, O., Santini, V., Sanz, G., Scheinberg, P., Stauder, R., Loosdrecht, A.A. van de, Wei, A.H., Sekeres, M.A., Fenaux, P., Zeidan, A.M., Platzbecker, U., Bewersdorf, J.P., Stahl, M., Adès, L., Borate, U., Bowen, D., Buckstein, R., Brunner, A., Carraway, H.E., Daver, N., Díez-Campelo, M., Witte, T.J. de, DeZern, A.E., Efficace, F., Garcia-Manero, G., Garcia, J.S., Germing, U., Giagounidis, A., Griffiths, E.A., Hasserjian, R.P., Hellström-Lindberg, E., Iastrebner, M., Komrokji, R., Kulasekararaj, A.G., Malcovati, L., Miyazaki, Y., Odenike, O., Santini, V., Sanz, G., Scheinberg, P., Stauder, R., Loosdrecht, A.A. van de, Wei, A.H., Sekeres, M.A., and Fenaux, P.

Abstract

Item does not contain fulltext, Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable clinical presentations and outcomes. The initial response criteria developed by the International Working Group (IWG) in 2000 have been used in clinical practice, clinical trials, regulatory reviews, and drug labels. Although the IWG criteria were revised in 2006 and 2018 (the latter focusing on lower-risk disease), limitations persist in their application to higher-risk MDS (HR-MDS) and their ability to fully capture the clinical benefits of novel investigational drugs or serve as valid surrogates for longer-term clinical end points (eg, overall survival). Further, issues related to the ambiguity and practicality of some criteria lead to variability in interpretation and interobserver inconsistency in reporting results from the same sets of data. Thus, we convened an international panel of 36 MDS experts and used an established modified Delphi process to develop consensus recommendations for updated response criteria that would be more reflective of patient-centered and clinically relevant outcomes in HR-MDS. Among others, the IWG 2023 criteria include changes in the hemoglobin threshold for complete remission (CR), the introduction of CR with limited count recovery and CR with partial hematologic recovery as provisional response criteria, the elimination of marrow CR, and specific recommendations for the standardization of time-to-event end points and the derivation and reporting of responses. The updated criteria should lead to a better correlation between patient-centered outcomes and clinical trial results in an era of multiple emerging new agents with novel mechanisms of action.

Published
2023

17. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

Author

Montalban-Bravo, G, Huang, X, Jabbour, E, Borthakur, G, DiNardo, C D, Pemmaraju, N, Cortes, J, Verstovsek, S, Kadia, T, Daver, N, Wierda, W, Alvarado, Y, Konopleva, M, Ravandi, F, Estrov, Z, Jain, N, Alfonso, A, Brandt, M, Sneed, T, Chen, H-C, Yang, H, Bueso-Ramos, C, Pierce, S, Estey, E, Bohannan, Z, Kantarjian, H M, and Garcia-Manero, G

Published
2017
Full Text
View/download PDF

18. P135 - Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

Author

Garcia-Manero, G., Bachiashvili, K., Griffiths, E., Traer, E., Saini, L., Amin, H., Zeidan, A., Mohan, S., Lübbert, M., Maness, L., Foran, J., Selleslag, D., Xicoy, B., Pollyea, D., Sallman, D., Al-Kali, A., Berdeja, J., Al-Ali, H., Zhu, N., Lopez, P. Font, Sanz, G., Santini, V., Yimer, H., Cripe, L., Priego, V., Odenike, O., Heyrman, B., Valcárcel, D., Vachhani, P., Sano, Y., Mirakhur, B., Oganesian, A., Keer, H., and Yacoub, A.

Published
2023
Full Text
View/download PDF

19. P136 - Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES

Author

Savona, M., Mccloskey, J., Griffiths, E., Yee, K., Zeidan, A., Al-Kali, A., Deeg, H.J., Patel, P., Sabloff, M., Keating, M.-M., Zhu, N., Gabrail, N., Fazal, S., Maly, J., Odenike, O., Kantarjian, H., Dezern, A., O’Connell, C., Roboz, G., Busque, L., Buckstein, R., Amin, H., Randhawa, J., Leber, B., Dao, K.-H., Sano, Y., Mirakhur, B., Keer, H., and Garcia-Manero, G.

Published
2023
Full Text
View/download PDF

21. P095 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE

Author

Pfeilstöcker, M., Tuechler, H., Ades, L., Cermak, J., Chermat, F., Della Porta, M., Fenaux, P., Garcia-Manero, G., Germing, U., Haase, D., Kündgen, A., Lübbert, M., Magalhaes, S., Malcovati, L., Miyazaki, Y., Sanz, G., Santini, V., Sekeres, M., Walter, M., Valent, P., and Greenberg, P.

Published
2023
Full Text
View/download PDF

22. P091 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)

Author

Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R., Sekeres, M., Della Porta, M., Cazzola, M., Dezern, A., Roboz, G., Steensma, D., Van De Loosdrecht, A., Malcovati, L., Schlenk, R., Grau, J., Calvo, X., Blum, S., Pereira, A., Valent, P., Costa, D., Giagounidis, A., Xicoy, B., Döhner, H., Platzbecker, U., Pedro, C., Lübbert, M., Oiartzabal, I., Diez-Campelo, M., Cedena, M.T., Machherndl-Spandl, S., Lopez-Pavia, M., Martinez-De-Sola, M., Stauder, R., Merchan, B., Ganster, C., Schroeder, T., Voso, M.T., Pfeilstöcker, M., Sill, H., Hildebrandt, B., Esteve, J., Cobo, F., Solé, F., Germing, U., Greenberg, P., Haase, D., and Sanz, G.

Published
2023
Full Text
View/download PDF

23. IS06 - SINGLE CELL DATA

Author

Ganan-Gomez, I., Chien, K., Adema, V., Ma, F., Yang, H., Montalban-Bravo, G., Rodriguez-Sevilla, J., Tan, L., Lorenzi, P., Clise-Dwyer, K., Garcia-Manero, G., and Colla, S.

Published
2023
Full Text
View/download PDF

26. TP53-mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

Author

Daver, NG, Maiti, A, Kadia, TM, Vyas, P, Majeti, R, Wei, AH, Garcia-Manero, G, Craddock, C, Sallman, DA, and Kantarjian, HM

Subjects
Oncology, Article
Abstract

TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) form a distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML have lower response rates to either induction chemotherapy, hypomethylating agent–based regimens, or venetoclax-based therapies compared with non–TP53-mutated counterparts and a poor median overall survival of 5 to 10 months. Recent advances have identified novel pathogenic mechanisms in TP53-mutated myeloid malignancies, which have the potential to improve treatment strategies in this distinct clinical subgroup. In this review, we discuss recent insights into the biology of TP53-mutated MDS/AML, current treatments, and emerging therapies, including immunotherapeutic and nonimmune-based approaches for this entity. Significance: Emerging data on the impact of cytogenetic aberrations, TP53 allelic burden, immunobiology, and tumor microenvironment of TP53-mutated MDS and AML are further unraveling the complexity of this disease. An improved understanding of the functional consequences of TP53 mutations and immune dysregulation in TP53-mutated AML/MDS coupled with dismal outcomes has resulted in a shift from the use of cytotoxic and hypomethylating agent–based therapies to novel immune and nonimmune strategies for the treatment of this entity. It is hoped that these novel, rationally designed combinations will improve outcomes in this area of significant unmet need.

Published
2022

32. P369: A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Author

Senapati, J., primary, Kantarjian, H., additional, Short, N., additional, Konopleva, M., additional, Ravandi, F., additional, Jain, N., additional, Thompson, P. A., additional, Pemmaraju, N., additional, Wierda, W. G., additional, Borthakur, G., additional, Kadia, T. M., additional, Garcia-Manero, G., additional, Yilmaz, M., additional, Thankachan, J., additional, Zhao, M., additional, Loiselle, C., additional, Talley, M. T., additional, Kwari, M. I., additional, Garris, R. S., additional, and Jabbour, E. J., additional

Published
2022
Full Text
View/download PDF

33. S160: MOLECULAR DETERMINANTS OF DISEASE PROGRESSION AFTER HYPOMETHYLATING AGENT THERAPY IN RAS PATHWAY MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA AT THE SINGLE-CELL LEVEL

Author

Montalban-Bravo, G., primary, Ma, F., additional, Ganan-Gomez, I., additional, Kanagal-Shamana, R., additional, Adema, V., additional, Thongon, N., additional, Yang, H., additional, Soltysiak, K. A., additional, Bueso-Ramos, C., additional, Kantarjian, H., additional, Garcia-Manero, G., additional, and Colla, S., additional

Published
2022
Full Text
View/download PDF

34. P770: A COMPARATIVE STUDY OF LEUKEMIC TRANSFORMATION IN THERAPY-RELATED AND DE NOVO MYELODYSPLASTIC SYNDROME AFTER HYPOMETHYLATING AGENT FAILURE

Author

Kim, K., primary, Ong, F., additional, Li, Z., additional, Kanagal-Shamanna, R., additional, Montalban-Bravo, G., additional, Kadia, T., additional, Jabbour, E., additional, Pemmaraju, N., additional, Hammond, D., additional, Short, N., additional, Ravandi, F., additional, Alvarado, Y., additional, Pierce, S., additional, Dong, X. Q., additional, Kantarjian, H., additional, Garcia-Manero, G., additional, and Chien, K., additional

Published
2022
Full Text
View/download PDF

35. P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

Author

Chien, K., primary, Kim, K., additional, Li, Z., additional, Kanagal Shamanna, R., additional, Ong, F., additional, Montalban Bravo, G., additional, Kadia, T., additional, Jabbour, E., additional, Pemmaraju, N., additional, Hammond, D., additional, Short, N., additional, Ravandi, F., additional, Alvarado, Y., additional, Pierce, S., additional, Dong, X. Q., additional, Kantarjian, H., additional, and Garcia-Manero, G., additional

Published
2022
Full Text
View/download PDF

36. P757: RESULTS OF A PHASE 1 STUDY OF AZACITIDINE COMBINED WITH VENETOCLAX FOR TREATMENT-NAIVE AND RELAPSED HIGH-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA

Author

Bazinet, A., primary, Jabbour, E., additional, Kantarjian, H., additional, Chien, K., additional, DiNardo, C., additional, Ohanian, M., additional, Daver, N., additional, Kanagal-Shamanna, R., additional, Kadia, T., additional, Takahashi, K., additional, Masarova, L., additional, Short, N., additional, Alvarado, Y., additional, Thompson, P., additional, Montalban-Bravo, G., additional, Yilmaz, M., additional, Ravandi, F., additional, Konopleva, M., additional, Andreeff, M., additional, Kornblau, S., additional, Pemmaraju, N., additional, Hammond, D., additional, Schneider, H., additional, Mirabella, B., additional, and Garcia-Manero, G., additional

Published
2022
Full Text
View/download PDF

37. P581: PHASE II STUDY OF LOWER-INTENSITY FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH AML WHO ARE UNFIT OR OTHERWISE NOT ELIGIBLE FOR FRONTLINE CLINICAL TRIALS

Author

Venugopal, S., primary, Jabbour, E., additional, Pemmaraju, N., additional, Montalban-Bravo, G., additional, Chien, K. S., additional, Daver, N., additional, Jain, N., additional, Burger, J., additional, Alvarado, Y., additional, Maiti, A., additional, DiNardo, C. D., additional, Borthakur, G., additional, Malla, R., additional, Garcia-Manero, G., additional, Ravandi, F., additional, Kantarjian, H., additional, and Kadia, T., additional

Published
2022
Full Text
View/download PDF

38. P541: OUTCOMES AND MANAGEMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PRESENTING WITH HYPERLEUKOCYTOSIS

Author

Haddad, F., primary, Sasaki, K., additional, Abuasab, T., additional, Venugopal, S., additional, Rivera Delgado, D., additional, Bazinet, A., additional, Babakhanlou, R., additional, Kim, K., additional, Senapati, J., additional, Ong, F., additional, Desikan, S., additional, Short, N., additional, Pemmaraju, N., additional, Borthakur, G., additional, DiNardo, C., additional, Daver, N., additional, Jabbour, E., additional, Garcia-Manero, G., additional, Ravandi, F., additional, and Kadia, T., additional

Published
2022
Full Text
View/download PDF

39. P781: CLINICAL OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION (HCRU) IN PATIENTS WITH LR-MDS REINITIATING ESAS FOLLOWING PREVIOUS ESA TREATMENT

Author

Garcia-Manero, G., primary, Matsuno, R. K., additional, McBride, A., additional, Brown, T. D., additional, Idryo, D., additional, Broome, R., additional, Herriman, A., additional, Johnson, T., additional, Wilkinson, K., additional, Walters, S., additional, Schrag, A., additional, Johanson, C., additional, Izano, M., additional, and Mukherjee, S., additional

Published
2022
Full Text
View/download PDF

40. P765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS)

Author

DiNardo, C. D., primary, Foran, J. M., additional, Watts, J. M., additional, Stein, E. M., additional, de Botton, S., additional, Fathi, A. T., additional, Prince, G. T., additional, Stone, R. M., additional, Patel, P. A., additional, Roboz, G. J., additional, Arellano, M. L., additional, Erba, H. P., additional, Pigneux, A., additional, Baratam, P., additional, Stuart, R. K., additional, Thomas, X., additional, Lemieux, I. R., additional, Bai, X., additional, Kapsalis, S. M., additional, Garcia-Manero, G., additional, and Sallman, D. A., additional

Published
2022
Full Text
View/download PDF

41. S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY

Author

Yilmaz, M., primary, Muftuoglu, M., additional, Kantarjian, H., additional, DiNardo, C., additional, Kadia, T., additional, Borthakur, G., additional, Pemmaraju, N., additional, Short, N., additional, Alvarado, Y., additional, Maiti, A., additional, Masarova, L., additional, Montalban Bravo, G., additional, Loghavi, S., additional, Patel, K., additional, Kornblau, S., additional, Jabbour, E., additional, Garcia-Manero, G., additional, Andreeff, M., additional, and Daver, N., additional

Published
2022
Full Text
View/download PDF

42. P774: CLINICAL OUTCOMES ASSOCIATED WITH AZACITIDINE MONOTHERAPY FOR TREATMENT-NAIVE PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

Author

Hasegawa, K., primary, Wei, A. H., additional, Garcia-Manero, G., additional, Daver, N. G., additional, Rajakumaraswamy, N., additional, Iqbal, S., additional, Chan, R. J., additional, Hu, H., additional, Tse, P., additional, Yan, J., additional, Zoratti, M. J., additional, Xie, F., additional, and Sallman, D. A., additional

Published
2022
Full Text
View/download PDF

43. S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS

Author

Garcia-Manero, G., primary, Winer, E. S., additional, DeAngelo, D. J., additional, Tarantolo, S., additional, Sallman, D. A., additional, Dugan, J., additional, Groepper, S., additional, Giagounidis, A., additional, Götze, K., additional, Metzeler, K. H., additional, Li, C.-C., additional, Zhou, L., additional, Martinez, E., additional, Lane, M., additional, von Roemeling, R., additional, Bohme, M., additional, Kubasch, A. S., additional, Verma, A., additional, and Platzbecker, U., additional

Published
2022
Full Text
View/download PDF

45. P767: CLINICAL SIGNIFICANCE OF ROUTINE HIGH-RESOLUTION STRUCURAL VARIANT PROFILING IN MYELODYSPLASTIC SYNDROMES

Author

Yang, H., primary, Garcia-Manero, G., additional, Sasaki, K., additional, Montalban-Bravo, G., additional, Tang, Z., additional, Wei, Y., additional, Kadia, T., additional, Chien, K., additional, Rush, D., additional, Nguyen, H., additional, Kalia, A., additional, Nimmakayalu, M., additional, Bueso-Ramos, C., additional, Kantarjian, H., additional, Medeiros, L. J., additional, Luthra, R., additional, and Kanagal-Shamanna, R., additional

Published
2022
Full Text
View/download PDF

46. P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA

Author

Senapati, J., primary, Ishizawa, J., additional, Abbas, H. A., additional, Loghavi, S., additional, Borthakur, G., additional, Issa, G. C., additional, Dara, S. I., additional, Pourebrahim, R., additional, Daver, N., additional, Jabbour, E. J., additional, Kornblau, S. M., additional, Pemmaraju, N., additional, Garcia-Manero, G., additional, Ravandi, F., additional, Muftuoglu, M., additional, Khoury, J., additional, DiNardo, C., additional, and Andreeff, M., additional

Published
2022
Full Text
View/download PDF

48. P495: PHASE 2 STUDY OF ASTX727 (DECITABINE/CEDAZURIDINE) PLUS VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR PREVIOUSLY UNTREATED, ELDERLY PATIENTS UNFIT FOR CHEMOTHERAPY

Author

Abuasab, T., primary, Alvarado, Y., additional, Issa, G., additional, Islam, R., additional, Short, N., additional, Yilmaz, M., additional, jain, N., additional, Masarova, L., additional, Kornblau, S., additional, Jabbour, E., additional, Pemmaraju, N., additional, Montalban-Bravo, G., additional, Pierce, S., additional, DiNardo, C., additional, Kadia, T., additional, Daver, N., additional, Konopleva, M., additional, Garcia-Manero, G., additional, and Ravandi, F., additional

Published
2022
Full Text
View/download PDF

49. P566: IMPACT OF FRONTLINE INDUCTION APPROACH ON POST-STEM CELL TRANSPLANT (SCT) OUTCOMES IN OLDER ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)

Author

Ong, F., primary, Ravandi, F., additional, Popat, U., additional, Kadia, T. M., additional, Daver, N., additional, DiNardo, C., additional, Konopleva, M., additional, Borthakur, G., additional, Shpall, E. J., additional, Oran, B., additional, Al-Atrash, G., additional, Mehta, R., additional, Jabbour, E. J., additional, Yilmaz, M., additional, Issa, G. C., additional, Garcia-Manero, G., additional, Maiti, A., additional, Abbas, H. A., additional, Champlin, R. E., additional, and Short, N. J., additional

Published
2022
Full Text
View/download PDF

50. P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYELOID CLINICAL TRIAL PROGRAM

Author

Zeidan, A. M., primary, Al-Kali, A., additional, Borate, U., additional, Cluzeau, T., additional, DeZern, A. E., additional, Esteve, J., additional, Giagounidis, A., additional, Kobata, K., additional, Lyons, R., additional, Platzbecker, U., additional, Sallman, D. A., additional, Santini, V., additional, Sanz, G. F., additional, Sekeres, M. A., additional, Wei, A. H., additional, Xiao, Z., additional, Van Hoef, M., additional, Nourry-Boulot, C., additional, Sadek, I., additional, Ma, F., additional, Iordan, A., additional, Sabo, J., additional, and Garcia-Manero, G., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results